01 November 2024
01 November 2024
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
Reeves' budget promised investment for innovation and R&D with a view to "harnessing the full potential of the UK鈥檚 science base鈥�.
EvolveImmune is now eligible for an aggregate of $65m in upfront fees and equity investment from AbbVie.
The EC鈥檚 decision marks the first instance of imposing a fine on a company for dual practices.
The measures taken as a result of losing the deal include cutting staff, which would occur with immediate effect.
Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs.
Under the terms of the agreement, Roche will pay Dyno Therapeutics $50m upfront, along with additional payments during the research phase of the collaboration.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
